| ||||
|
|
|
||
|
|
||||||||||||||||||||||||||
| ||
| Features: | |
|
| ||
|
 |
|
|
|
|
 JAMWA is the official publication of AMWA. Click the above image to learn more about AMWA. |
 Support for the editorial office of JAMWA is provided by Columbia University School of Public Health, Center for Population and Family Health |
|
| "The goal of screening is to improve a medical outcome for the patient... The identification of a condition or risk factor through screening is not the end, but the beginning. To benefit the patient, the identification of a condition must be followed by an intervention that improves her health outcome. Many risk factors have treatments, so it seems worthwhile to screen the patient and get that opportunity for early intervention."(JAMWA. 2000; 55 :206) |
| "More than a decade has passed since the introduction of mifepristone, then called RU486, in France. Potential roles for this new drug class – able selectively to block the effects of progesterone – included applications for cancer treatment and management of hormone disorders. Most obvious, however, was its potential to improve early options for abortion. Since 1988, clinicians and women in the United States have been waiting to see this potential realized." (JAMWA. 2000; 55 :115) |
Click here to answer the forum question: The need for screening tests (like mammograms and Pap smears) often motivates women to see a health care provider on a regular basis. However, recent guidelines suggest that less frequent screening may be appropriate for some women. In your practice, how do you balance the tension between screening women less frequently, according to evidence-based and cost-effective guidelines, and maintaining regular, yearly contact? |
Sign up to receive automatic email updates and announcements about upcoming issues of JAMWA, chat sessions, forum discussion, and more. |
